Skip to content
‹ Back to IndustriesHealthcare

The Continued Democratization of Personalized Healthcare

A show of hands: How many people were adept at taking an in-home health test before the pandemic? The answer: probably not many. The pandemic changed that, along with so many other healthcare processes. Taking a COVID test, a healthcare assessment, or even a virtual patient visit weren’t things most were used to doing at…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Highway to Health on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

A show of hands: How many people were adept at taking an in-home health test before the pandemic? The answer: probably not many. The pandemic changed that, along with so many other healthcare processes. Taking a COVID test, a healthcare assessment, or even a virtual patient visit weren’t things most were used to doing at home a few short years ago, but the experience taught millions of people a valuable lesson: personalized healthcare is essential and should be a part of the healthcare journey moving forward.

Technology is leading the way in democratizing personalized healthcare. Wearable technology, from fitness monitoring to biosensors, can give patients and providers valuable health information and provide new tools for improving health outcomes. Advanced data gathering creates health equity for everyone.

David Kemp, host of Highway to Health, spoke with two women working on the front lines of that personalized healthcare mission. Sherlock Biosciences’ Julie Garlikov, Chief Commercial Officer, and Karen Davies, Chief Development Officer, gave Kemp a window into the science behind molecular diagnostics, which is changing the game of testing to a more democratized and decentralized approach to personalized healthcare.

What types of testing does Sherlock Biosciences do?

“We’re a pre-commercial company looking at the intersection of our chemistries and technologies and where our tests perform the best,” Garlikov said. “And then we talked with many consumers to understand where they want to test and what they want to test for at home. And when we put those two together, the intersection is in the areas of respiratory and sexual health. And when I say respiratory, I’m not just talking COVID tests. I’m talking about flu, or RSV, or even, in the future, strep throat, or walking pneumonia.”

Kemp’s conversation with Garlikov and Davies includes the following:

  • Creating efficiencies through at-home testing
  • The advancing technologies creating these new testing solutions
  • The importance of advanced diagnostics for rural and underserved communities

“Accessibility is the big thing,” Davies said. “And portability. A small, easy-to-run test; you can stick it in your backpack, you can stick it in your suitcase, or you can mail order it if you live in a remote region. If I’ve got that test in my backpack or I’ve got that test at home, I can run it. It’s negative most of the time. And so I can provide self-care. If it’s positive, I know it’s worth the trip to see my doctor.”

About Karen

Karen Davies is a mechanical engineer with a BS from Stanford University. Her twenty-plus-year career in medical devices includes product development, technical leadership, program management, quality and regulatory compliance, and strategic planning. She is a sought-out mentor by personnel in multiple functional areas, including Instrumentation, Assay Development, and Marketing.

About Julie

Julie Garlikov is a full-stack, omnichannel, B2C/B2B marketing & commercialization executive with numerous successes in accelerating growth for digital consumer healthcare and health, wellness & beauty (skincare, vitamins, nutrition), and beverage brands. Her passion lies in building and scaling brands to take them to the next level. Garlikov holds an MBA in marketing from Columbia Business School and a BA from the University of California, Berkeley.

Highway to Health

Part of this channel

Highway to Health

Healthcare innovation conversations for executives and technology buyers.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris Life Sciences completed approximately 61,500 clinical cases in Q3 2026 and raised 2026 revenue guidance to $1.04-$1.05 billion. Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a minimal residual disease assay, is targeted to launch before year-end.

  • 01Caris said higher operating expenses were driven primarily by headcount-related costs, research and development investment and marketing.
  • 02Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a whole genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
  • 03Caris reaffirms its guidance for clinical therapy selection volume growth of approximately 20%.

Nov 8, 2026

Denials get a queue, underpayments just look like paid claims

Denials get a queue, underpayments just look like paid claims

Underpayments in healthcare revenue cycle operations lack the visibility of denied claims because they don't trigger alerts or queue workflows. Without dedicated ownership and line-level verification against contract terms, paid claims that fall short of their contractual amount pass through undetected.

  • 01Denial workflows activate on rejection events, but underpayments produce no event, leaving paid claims unverified by default.
  • 02The speaker says many provider groups lack line-level contract intelligence to check each paid line against the applicable terms.
  • 03Payment received and payment checked are separate tasks: one verifies acceptance, the other verifies correctness—and the second often has no assigned owner.

Nov 6, 2026

A zero-paid claim line is not automatically an underpayment

A zero-paid claim line is not automatically an underpayment

A zero payment on a claim line isn't automatically an underpayment; contract terms, particularly packaging rules, determine whether zero is correct. Chasing unsupported findings damages credibility with payers and weakens the position of legitimate disputes, so revenue cycle teams must verify the full contract terms and effective dates before treating any payment difference as a finding.

  • 01When a contract packages add-ons into the primary procedure, the add-on line may legitimately show zero payment because it is folded into the primary procedure reimbursement.
  • 02Pursuing payment differences that lack contract support burns credibility with payers and can weaken the team’s position on later disputes, including valid ones.
  • 03Always verify the complete contract terms, fee schedules, carve-outs, amendments, and the specific version in effect on the date of service before treating a payment variance as a recoverable underpayment.

Nov 6, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512